Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
Journal of the American Society of Hypertension : JASH
|
February 5, 2015
Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?
Murray Epstein, Eduardo de Marchena
Cleveland Clinic Journal of Medicine
|
February 1, 2023
The constellation of vitamin D, the acute-phase response, and inflammation
Maria J Antonelli, Irving Kushner, Murray Epstein
Journal of Cardiac Failure
|
May 21, 2020
Defining the Optimal Dialysis Regimen for Improving Left Ventricular Structure and Function: An Urgent Need
Murray Epstein, David L Epstein, Daniel Duprez
Cleveland Clinic Journal of Medicine
|
September 1, 2023
Why 25-dehydroxyvitamin D is a negative acute-phase reactant
Maria J Antonelli, Irving Kushner, Murray Epstein
Journal of Clinical Pharmacology
|
November 17, 2004
Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy
Arif Asif, David L Epstein, Murray Epstein
Kidney International
|
February 17, 2012
Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms
Linda Shavit, Meyer D Lifschitz, Murray Epstein
The American Journal of Medicine
|
September 20, 2020
The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future
João Pedro Ferreira, Murray Epstein, Faiez Zannad
The American Journal of Medicine
|
August 22, 2012
Hypertension and chronic kidney disease progression: why the suboptimal outcomes?
Anil K Bidani, Karen A Griffin, Murray Epstein
Hypertension (Dallas, Tex. : 1979)
|
March 27, 2020
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
A H Jan Danser, Murray Epstein, Daniel Batlle
Journal of the American Society of Nephrology : JASN
|
June 7, 2005
Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?
Vito M Campese, Mitra K Nadim, Murray Epstein
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
Journal of the American Society of Hypertension : JASH
|
February 5, 2015
Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?
Murray Epstein, Eduardo de Marchena
Cleveland Clinic Journal of Medicine
|
February 1, 2023
The constellation of vitamin D, the acute-phase response, and inflammation
Maria J Antonelli, Irving Kushner, Murray Epstein
Journal of Cardiac Failure
|
May 21, 2020
Defining the Optimal Dialysis Regimen for Improving Left Ventricular Structure and Function: An Urgent Need
Murray Epstein, David L Epstein, Daniel Duprez
Cleveland Clinic Journal of Medicine
|
September 1, 2023
Why 25-dehydroxyvitamin D is a negative acute-phase reactant
Maria J Antonelli, Irving Kushner, Murray Epstein
Journal of Clinical Pharmacology
|
November 17, 2004
Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy
Arif Asif, David L Epstein, Murray Epstein
Kidney International
|
February 17, 2012
Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms
Linda Shavit, Meyer D Lifschitz, Murray Epstein
The American Journal of Medicine
|
September 20, 2020
The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future
João Pedro Ferreira, Murray Epstein, Faiez Zannad
The American Journal of Medicine
|
August 22, 2012
Hypertension and chronic kidney disease progression: why the suboptimal outcomes?
Anil K Bidani, Karen A Griffin, Murray Epstein
Hypertension (Dallas, Tex. : 1979)
|
March 27, 2020
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
A H Jan Danser, Murray Epstein, Daniel Batlle
Journal of the American Society of Nephrology : JASN
|
June 7, 2005
Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?
Vito M Campese, Mitra K Nadim, Murray Epstein
Page
of 8